{"classes":[{"categories":[{"measurements":[{"comment":"NA: The Median and the upper limit of Confidence Interval could not be reached because fewer than half of the patients experienced an event","groupId":"OG000","lowerLimit":"10.0","upperLimit":"NA","value":"NA"},{"comment":"NA: The Median and the upper limit of Confidence Interval could not be reached because fewer than half of the patients experienced an event","groupId":"OG001","lowerLimit":"1.2","upperLimit":"NA","value":"NA"},{"comment":"NA: The Median and the upper limit of Confidence Interval could not be reached because fewer than half of the patients experienced an event","groupId":"OG002","lowerLimit":"10.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"61"}],"units":"Participants"}],"description":"DOR is the time from achievement of CR or PR, whichever occurs first, to relapse or death due to diffuse large B-cell lymphoma (DLBCL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG001","title":"Tisagenlecleucel - Cohort A"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US and at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - All Patients"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel and who achieved a completer response (CR) or a partial response (PR).","reportingStatus":"POSTED","timeFrame":"up to approx. 60.1 months","title":"Duration of Overall Response (DOR) Per IRC","type":"SECONDARY","unitOfMeasure":"Months"}